177 related articles for article (PubMed ID: 37289162)
1. [Preserving the oral health of patients on antiresorptive drugs].
Tilotta F; Folliguet M; Radoï L
Rev Prat; 2023 Apr; 73(4):421-429. PubMed ID: 37289162
[TBL] [Abstract][Full Text] [Related]
2. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
3. Antiresorptive treatment-associated ONJ.
Eleutherakis-Papaiakovou E; Bamias A
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
[TBL] [Abstract][Full Text] [Related]
4. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
5. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
[TBL] [Abstract][Full Text] [Related]
6. Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.
Laimer J; Hechenberger M; Müller D; Walch B; Kolk A; Schnabl D; Schomaker M; Bruckmoser E
Future Oncol; 2021 Jul; 17(21):2705-2711. PubMed ID: 33880956
[No Abstract] [Full Text] [Related]
7. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
8. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
9. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced osteonecrosis of the jaw: the state of the art.
Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
[TBL] [Abstract][Full Text] [Related]
11. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
12. [Osteonecrosis of the jaws (ONJ) associated to antiresorptive treatment].
Larsson Wexell C; Kjellman A; Akre O
Lakartidningen; 2018 May; 115():. PubMed ID: 29809272
[TBL] [Abstract][Full Text] [Related]
13. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.
Goodday RH
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):527-36. PubMed ID: 26293331
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
Halpern LR; Adams DR
Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
[TBL] [Abstract][Full Text] [Related]
15. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Fusco V; Campisi G; Bedogni A
Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
[TBL] [Abstract][Full Text] [Related]
16. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
[TBL] [Abstract][Full Text] [Related]
18. Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Chaurand-Lara J; Pacheco-Ruiz L; Trejo-Campos JL; Facio-Umaña JA; Mora-Pérez J
Cir Cir; 2019; 87(4):396-401. PubMed ID: 31264983
[TBL] [Abstract][Full Text] [Related]
19. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
20. [Bisphosphonate-related osteonecrosis of the jaws].
Sogacheva VV; Syomkin VA
Stomatologiia (Mosk); 2022; 101(6):85-90. PubMed ID: 36562373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
